Abstract 48P
Background
Deciphering the role of the adaptive immune system is key to fully realize the potential of immuno-oncology in CCA. TILs are components of the immune microenvironment with a prognostic value across cancer types yet understudied in CCA.
Methods
Tissue blocks from 70 CCA pts undergoing radical surgery between 2013-2023 at the University Hospital of Modena were retrieved. IHC for CD4, CD8 and Foxp3 was performed for the intratumoural (i) and stromal (s) compartment. TILs were recorded as continuous variables and dichotomized to the median. Both bulk RNAseq and spatial trascriptomics were applied through TempO-seq and GeoMx. Correlation analyses and survival models were performed using IBM SPSS Statistics version 25.0.
Results
55% and 42% pts had iCD4+high and sCD4+high CCAs, 54% and 27% of them had iCD8+high and sCD8+high CCAs, and 28% and 34% of them had iFoxp3+high and sFoxp3+high CCAs. iCD4+ high CCAs were associated with pN0 status and a significantly longer RFS than CD4+ low cases (p=0.02). Contrariwise, pts with increased iCD8+ T cell density had significantly shorter RFS than iCD8+ T cells low tumours (p=0.05). iCD4+ T cells together with ECOG PS, nodal status, and adjuvant chemotherapy were independent predictors of outcome. Among iCD4+ high cases, adjuvant chemotherapy significantly prolonged survival compared to observation alone (p=0.01), while no difference was seen within the iCD4+ low subgroup (p=0.06). Compared to CCAs with lower TILs infiltration, iCD4+ high and iCD8+high subsets exhibited 342 and 393 differentially expressed genes, enriched in metabolic, beta-catenin and KRAS pathways and interferon alfa, DNA repair and VEGF networks, respectively.
Conclusions
More than 50% of CCAs displayed high intratumour infiltration of CD4+ and CD8+ TILs, which defined transcriptionally distinct entities with different clinical implications. Interestingly, higher iCD4+ density predicted a favourable prognosis and a benefit from adjuvant chemotherapy in our cohort. These preliminary findings prompt future studies diving into the biomarker potential of TILs in CCA.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Azienda Ospedaliero Universitaria di Modena.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2008P - Assessing response durability and survival after second-line pembrolizumab in advanced urothelial carcinoma: A multicenter validation of a risk model
Presenter: Samer Salah
Session: Poster session 13
2010P - Trifunctional anti-EpCAM/CD3 bsAb catumaxomab intravesically for high and intermediate risk non muscle invasive bladder cancer (HMR-NMIBC): Interim analysis of a phase I study
Presenter: Aleksander Antoniewicz
Session: Poster session 13
2011P - Neoadjuvant immunotherapy-driven bladder preservation for muscle-invasive bladder cancer: A multicenter, propensity score-matched cohort study
Presenter: Jiao Hu
Session: Poster session 13
2012P - Role of first-line immunotherapy in urothelial cancer with bone metastases: A national cancer database analysis of 3971 patients
Presenter: Zin Myint
Session: Poster session 13
2013P - First preliminary results of artificial intelligence generated treatment recommendations for urothelial cancer based on multidisciplinary cancer conferences from the KITTU project
Presenter: Gregor Duwe
Session: Poster session 13
2014P - Overall survival (OS) results in phase II trial of cabozantinib (CABO) plus durvalumab (DURVA) in patients with urothelial carcinoma (UC) or non-UC variant histologies (VH) after platinum chemotherapy (ARCADIA)
Presenter: Patrizia Giannatempo
Session: Poster session 13
2015P - Serum nectin-4: Prognostic and predictive value in bladder cancer?
Presenter: Kerstin Junker
Session: Poster session 13
2016P - Evaluation of event-free survival (EFS) as a surrogate endpoint for overall survival (OS) in muscle-invasive bladder cancer (MIBC) following neoadjuvant (NAD) therapy
Presenter: Cora Sternberg
Session: Poster session 13
2017P - Intrinsic molecular difference between bladder and upper tract urothelial carcinomas and its impacts in treatment response
Presenter: Jiwon Kim
Session: Poster session 13